Liquidia Reaches $380.7M Global Litigation Settlement with United Therapeutics

Liquidia Corporation has entered into a global settlement agreement with United Therapeutics Corporation (UTC) to resolve all ongoing litigation between the two companies. As part of the agreement, Liquidia will make net payments totaling approximately $380.7 million and remove the PH-ILD indication from its YUTREPIA® product label. The settlement ensures that YUTREPIA will remain commercially available for the treatment of pulmonary arterial hypertension (PAH).

Key Details

• Financial Terms: Liquidia will make total settlement payments of approximately $380.7 million. This includes a net payment of $175.0 million to UTC within 30 business days, two additional installments to UTC totaling $145.4 million due in 2027, and payments of $60.3 million to other parties to resolve related antitrust litigation.
• Operational Terms: Liquidia will continue to market YUTREPIA® for PAH but will file with the FDA to remove the indication for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and will immediately cease all marketing and promotion for the PH-ILD indication.
• Financial Position: The company disclosed preliminary unaudited Q3 2026 results, including YUTREPIA net product sales of $222.7 million and a cash and cash equivalents balance of $396.1 million as of September 30, 2026.